Vazyme to Reveal Its Latest COVID-19 Testing Products and Solutions at MEDICA 2021
PR92738
DUSSELDORF, Germany, Nov. 8, 2021 /PRNewswire=KYODO JBN/ --
Chinese biotechnology company Nanjing Vazyme Biotech Co., Ltd (Vazyme) will
exhibit its advanced COVID-19 testing products and solutions in Hall 3 Stand F
94 at MEDICA 2021, the world's leading trade fair for the medical sector, in
Messe Düsseldorf (Germany) from November 15 to November 18. The event provides
visitors with a broad range of innovative medical products and solutions
accompanied by ideas exchange and expert dialogues in specialist forums in
order to better understand the trends of the healthcare industry.
Vazyme will reveal its full lineup of COVID-19 related products and solutions
at the event, with a focus on the debut of the company's latest virus testing
product – SARS-CoV-2 & FLU A/B RT-QPCR and SARS-CoV-2 & FLU A/B Ag Rapid Test,
both of which are able to test and detect three types of virus including
COVID-19 and influenza A/B simultaneously, achieving more efficient and
comprehensive virus testing.
Since the pandemic hit, Vazyme has been constantly rolling out a series of
COVID-19 testing reagents and related devices for nucleic acid detection
solution, rapid antigen, rapid antibody, and rapid neutralizing antibody tests.
Vazyme's products improve COVID-19 testing in the fight against the crippling
pandemic with more accurate, reliable, and rapid testing results. Vazyme has
provided COVID-19 testing products and solutions to multiple countries and
regions including Germany, UK, Russia, Brazil, and Indonesia, and has supplied
key raw materials for over 500 million COVID-19 testing kits to testing kit
manufacturers globally.
Vazyme will showcase more COVID-19 diagnostic products and solutions including:
-Nucleic Acid Detection Solution
-SARS-CoV-2 Ag Rapid Test
-SARS-CoV-2 Ag Home Test
-SARS-CoV-2 & FLU A/B Ag Rapid Test
-Neutralizing Ab Detection
-Etc.
The global in vitro diagnostics market has seen remarkable growth, along with
the demands of comprehensive, accurate, customized diagnostic solutions. With
years of experience of developing products in this field, Vazyme's in vitro
diagnostic products have covered various specialties including cardiology,
prenatal and postnatal care, gastroenterology, nephrology, infection, and
pediatric pulmonology.
Apart from Point-of-Care Testing (POCT) diagnostic devices, as a leading
upstream medical raw material supplier, Vazyme aims to provide its clients with
the best products and services in medical raw materials. As one of the few
research and development (R&D)-focused innovative producers in China with
capabilities in developing upstream technologies in-house and manufacturing
finished products, Vazyme upholds the vision to improve human life with
technology and focuses on continuous investment in technological innovation and
quality products.
To further reach billions of customers globally, Vazyme is accelerating the
expansion of its footprint in overseas markets, with a focus on developing the
European market by building extensive local operations. Currently Vazyme is
working with world renowned academic institutions to establish multinational
labs and partnering with leading medical and pharmaceutical distributors in
overseas markets to build localized sales and distribution networks. Vazyme is
looking forward to engaging with more global partners at MEDICA 2021.
About Vazyme
Founded in 2012, Vazyme is one of the few R&D-focused innovative biotechnology
firms in China that has capabilities in developing upstream technologies
in-house and manufacturing finished products. With an ongoing commitment to
innovation and based on its proprietary key generic technology platform, the
company has built a business network spanning biological research, in vitro
diagnosis and biomedicine. Vazyme has developed eight series of proprietary
POCT diagnostic reagents and related control materials covering cardiovascular
and cerebrovascular diseases, inflammation, prepotency, gastric functions,
autoimmunity, renal functions, chronic disease management as well as
respiratory diseases.
For more information, please visit Vazyme's official website at
Source: Vazyme
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=406002
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。